Neoadjuvant Therapy with Concurrent Docetaxel, Epirubicin, and Cyclophosphamide (TEC) in High-Risk HER2-Negative Breast Cancers.
Adv Ther
; 38(12): 5752-5762, 2021 12.
Article
in En
| MEDLINE
| ID: mdl-34699004
ABSTRACT
INTRODUCTION:
Concurrent anthracycline and taxane is an effective and efficient way to deliver neoadjuvant chemotherapy for HER2-negative breast cancers. Data on efficacy and tolerance to 6 cycles of concurrent docetaxel, epirubicin, and cyclophosphamide (TEC) is limited.METHOD:
All patients with HER2-negative breast cancers who received neoadjuvant TEC from January 2013 to December 2019 were reviewed.RESULTS:
A total of 71 patients [57 luminal B disease; 14 triple negative breast cancer (TNBC)] received neoadjuvant TEC with prophylactic granulocyte colony-stimulating factor (G-CSF). The pathological complete response (pCR) rate was 26.3% and 28.6% for luminal B and TNBC, respectively. With median follow-up of 48.9 months, 3 years disease-free survival was 85.9%, and 3 years overall survival was 89.6%. Non-hematological toxicities were common but the majority was grade 1 or 2. The most common grade 3 or 4 toxicity were hematological, including neutropenia (26.8%) and anemia (15.5%). There was no cardiotoxicity observed. Half of the patients had at least one dose reduction but all patients completed the planned 6 cycles and had breast surgery done.CONCLUSION:
Six cycles of TEC with prophylactic G-CSF is an effective and tolerable neoadjuvant regime for HER2-negative breast cancers. Hematological toxicities were the most common toxicities. Although many patients required dose reduction, all patients completed treatment and there was no observed cardiotoxicity.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Triple Negative Breast Neoplasms
Type of study:
Etiology_studies
/
Risk_factors_studies
Limits:
Female
/
Humans
Language:
En
Year:
2021
Type:
Article